Pioneering the Development of Automated Technologies for Cell-Based Therapeutics and Bioprocessing

For more than two decades ThermoGenesis Holdings, Inc. has developed and commercialized novel cell processing systems and devices providing global researchers, biomanufacturing organizations and clinicians with highly efficient cell processing devices which helped them to deliver better outcomes in various applications in the cell and gene therapy field.

Clinical BioBanking
With over 20 years of providing cord blood to banks hospitals, researchers and stem clinicians with systems designed to handle stem cells with the highest level of precision, safety, and confidence.
Point-of-Care Solutions
We develop products to obtain bone marrow concentrates easily, consistently, and reliably from bone marrow aspirates at the point-of-care with minimal red blood cell contamination.
Cellular Processing
The first step in the process is often the most important. That's why we have created closed-system novel and innovative technologies aimed at advancing cell therapies to the clinic.

Recent News

ThermoGenesis Holdings Begins a Year of Celebration of its 35th Anniversary in the Cell Banking and Cell Therapy Industry

Future corporate strategy targets large-scale cellular manufacturing needs for upcoming cell and gene therapies RANCHO CORDOVA, Calif., Feb. 17, 2021 — ThermoGenesis Holdings, Inc. (“ThermoGenesis” or the “Company”) (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, announced today that the Company will kick off a … Continued

Frequently Asked Questions About Cell and Gene Therapies

Cell and gene therapy are relatively new forms of medical treatment, having only been developed about 30 years ago. As such, there is a lot that the general public has yet to understand about these practices. Here, we answer the most commonly asked questions about cell and gene therapies.   What is Cell Therapy? Cell … Continued

ThermoGenesis Holdings Launches a GMP Compliant Automated Cell Washing and Reformulation System — PXP™-LAVARE — for CAR-T Manufacturing

RANCHO CORDOVA, Calif., Feb. 3, 2021 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that it has completed the development process, submitted a Letter to File and updated the device listing with the U.S. Food and Drug Administration (FDA) … Continued

The Successes and Challenges of CAR T-cell Therapy 

The four pillars of cancer treatment have always been surgery, chemotherapy, radiation therapy and targeted therapy. Recently, there have been developments leading to what scientists and medical professionals are referring to as the fifth pillar — immunotherapy.  Immunotherapy, or therapy that utilizes a patient’s own immune system to help illnesses, has been proven to be … Continued

Bone Marrow Aspirate Concentrate vs. Surgical Intervention

From injuries that can happen in an instant to normal wear-and-tear from physical activity over time, when there is something wrong with your joints or ligaments, it can cause discomfort and pain that can severely disrupt your way of life. Sometimes, the best way to correct these issues is through surgery, but many physicians will … Continued

ThermoGenesis Holdings to Participate at the H.C. Wainwright BIOCONNECT 2021 Conference

RANCHO CORDOVA, Calif., Jan. 7, 2021 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO) a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that Jeff Cauble, Chief Financial Officer, will present a company overview at the H.C. Wainwright BIOCONNECT 2021 Conference. The presentation will be available beginning January … Continued

Click below and be the first to hear about the latest news, breakthroughs, and products with the ThermoGenesis newsletter delivered directly to your inbox.
How may we help?